Chemistry Reference
In-Depth Information
Cellular viability (%)
180
MO/DOPE-PEG
2000
/EPA
MO/DOPE-PEG
2000
/AO
DMPC/DOPE-PEG
2000
/EPA
160
140
120
100
80
60
40
20
0
2,1E-05
8,4E-06
4,2E-06
8,4E-07
4,2E-07
8,4E-08
4,2E-08
4,2E-09
Total lipid concentration (mol/L)
Figure 11.13
Viability of differentiated SH-SY5Y cells treated with MO/DOPE-
PEG
2000
/EPA (83/2/15 mol %), MO/DOPE - PEG
2000
/OA (83/2/15 mol %) and DMPC/
DOPE- PEG
2000
/EPA (83/2/15 mol %) in the presence of BDNF (2 ng/ml or 4
1 0
− 8
n g /
cell) assessed by MTT test at 37°C. The histograms are presented in a sequence of
decreasing total lipid concentrations and expressed relative to the results obtained for
treatment of differentiated cells with BDNF alone.
×
The cell viability, established for the MO/DOPE-PEG
2000
/EPA (83/2/15 mol
%) and DMPC/DOPE-PEG
2000
/EPA (83/2/15 mol %) nanodispersions, was
compared to that determined for the ethanol solution of EPA (Fig. 11.14). The
EPA solution considerably enhances the effects of BDNF and nearly doubles
the overall cellular viability of the differentiated cells, except for 10
M con-
centration, which leads to about 50% decrease in the BDNF-mediated cellular
viability. These results are in correlation with those for differentiated cells
treated with EPA and 1 ng/ml BDNF (Kou et al., 2008). The comparison sug-
gests that the neuroprotection phenomenon is dependent on the concentration
of BDNF and that the cellular viability, enhanced by EPA, should be greater
in the presence of 2 ng/ml BDNF. The two lipid systems, containing 15 mol %
EPA, do not appear toxic at low concentrations of EPA up to 6
μ
1 0
− 7
M .
Beyond this concentration, the NP formulations induce 50% cell toxicity in
the investigated model.
The morphology of alive, unfi xed SH-SY5Y cells was studied by phase
contrast microscopy. Images were acquired for different treatments as indi-
cated in Figure 11.15. A change in the morphology (more elongated cells) and
×
Search WWH ::
Custom Search